Enclomiphene Citrate vs AndroGel: Side-Effect Profile Head-to-Head

How These Two Drugs Work Differently

Enclomiphene citrate and AndroGel both raise serum testosterone, but they do so from opposite ends of the hypothalamic-pituitary-testicular (HPT) axis. That mechanistic split determines nearly every side-effect difference between them.

Enclomiphene is the trans-isomer of clomiphene citrate. It blocks estrogen receptors in the hypothalamus, removing negative feedback and prompting the pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1]. Because LH stimulates the Leydig cells and FSH supports the Sertoli cells, endogenous testosterone rises while spermatogenesis continues. Kim et al. demonstrated this in a 2016 BJU International study: men with secondary hypogonadism treated with enclomiphene achieved normalized testosterone levels without suppressing sperm parameters 1.

AndroGel (testosterone gel 1%) bypasses the HPT axis entirely. The gel delivers exogenous testosterone through the skin into systemic circulation [2]. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older, confirmed that daily application of testosterone gel raised serum testosterone into the mid-normal range within weeks 2. That exogenous supply, however, sends a suppressive signal to the pituitary. LH and FSH fall. Spermatogenesis slows or stops.

This axis-level distinction is the root cause of the divergent side-effect profiles detailed below.

Fertility and Spermatogenesis: The Largest Clinical Divide

The single most consequential difference between these drugs is their effect on male fertility. This factor alone can rule one option in or out.

Exogenous testosterone acts as a male contraceptive. The Endocrine Society's 2018 clinical practice guideline states: "Testosterone therapy should not be initiated in men who are currently trying to conceive" 3. A systematic review published in Fertility and Sterility found that exogenous testosterone induced azoospermia or severe oligospermia in up to 90% of men within 10 weeks of starting treatment, though recovery occurred in most men within 6 to 12 months after discontinuation 4.

Enclomiphene sits on the other end of this spectrum. By raising FSH alongside LH, the drug maintains and can even improve sperm production. The Kim et al. trial showed that men on enclomiphene citrate 25 mg daily maintained normal sperm concentration and motility over a 12-week treatment period [1]. This makes enclomiphene the preferred pharmacologic option for hypogonadal men who want to preserve fertility or who have not yet completed family planning.

The American Urological Association's 2018 guideline on male infertility recommends clomiphene citrate (enclomiphene's parent compound) as an alternative to testosterone replacement in men who wish to maintain fertility 5. No comparable recommendation exists for AndroGel or any exogenous testosterone formulation in the fertility-preserving context.

Cardiovascular Risk Signals

Cardiovascular safety has been the most debated topic in testosterone replacement therapy for over a decade. The two drugs carry different regulatory warnings.

In 2015, the FDA added a general warning to all approved testosterone products, including AndroGel, stating that these products may increase the risk of heart attack and stroke 6. That warning was informed by two observational studies and one randomized trial (the TOM trial) that were stopped early after an excess of cardiovascular events in the testosterone arm 7.

The picture shifted with the TRAVERSE trial, a large randomized cardiovascular outcomes study (N=5,246) published in the New England Journal of Medicine in 2023. TRAVERSE found that testosterone replacement therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months (hazard ratio 0.99; 95% CI 0.81 to 1.21) 8. Dr. Shalender Bhasin, the study's principal investigator, stated: "These results should provide reassurance that testosterone replacement therapy does not increase the short- to medium-term risk of major adverse cardiovascular events" [8].

Enclomiphene lacks a comparable cardiovascular outcomes trial. Short-term studies have not identified a concerning signal. A theoretical advantage exists: because enclomiphene does not raise testosterone above the physiologic range the way supraphysiologic dosing can with gels, the drug may carry lower cardiovascular risk. But this remains unproven. No head-to-head cardiovascular comparison between enclomiphene and AndroGel exists.

Clinicians should note that the TRAVERSE trial also revealed a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm, though these were secondary endpoints and did not reach statistical significance after multiplicity adjustment [8].

Erythrocytosis and Hematocrit Elevation

Exogenous testosterone stimulates erythropoiesis. Dose-dependent. Predictable. Sometimes dangerous.

AndroGel prescribing information reports that hematocrit exceeding 54% occurred in approximately 1.2% of subjects during clinical trials 9. The Endocrine Society guideline recommends checking hematocrit at baseline, 3 to 6 months after starting therapy, and annually thereafter. The guideline advises stopping testosterone if hematocrit exceeds 54% and restarting at a lower dose after phlebotomy or after hematocrit normalizes [3].

Enclomiphene raises endogenous testosterone, which does stimulate some degree of erythropoiesis. But because levels tend to normalize within the physiologic range rather than spiking, the incidence of clinically significant polycythemia appears lower. Published enclomiphene trials have not reported polycythemia as a common adverse event [1]. This does not mean the risk is zero. It means it has not been quantified in a large enough dataset.

For patients with baseline hematocrit above 50%, sleep apnea, or chronic lung disease, this distinction matters clinically. Those patients face higher risk on exogenous testosterone and may benefit from enclomiphene's lighter erythropoietic effect.

Skin and Application-Site Reactions

AndroGel is a topical formulation. Enclomiphene is an oral capsule. That delivery route difference creates a side-effect category that applies only to AndroGel.

Application-site reactions (including pruritus, blistering, erythema, and dryness) occurred in 5.5% of men using AndroGel 1% in registration trials [9]. These reactions are typically mild and self-limiting, but they contribute to treatment discontinuation in clinical practice. A secondary concern is the 2 to 4 hour drying time required after application, during which the gel can transfer to others through direct skin contact.

The FDA's 2009 boxed warning on AndroGel specifically addresses virilization in children and women who had secondary contact with men using testosterone gel products 10. Reported cases included genital enlargement, premature pubic hair development, and advanced bone age in children exposed to testosterone through skin contact with a treated adult. The Endocrine Society's guideline for testosterone therapy advises: "Patients should be counseled to cover the application site with clothing after the gel has dried and to wash the area before skin-to-skin contact with others" [3].

Enclomiphene, taken orally, carries no risk of secondary transfer. No application-site reactions. No drying time. For men with household members who include young children or pregnant partners, this can be a deciding factor.

Estrogen-Related and SERM-Specific Side Effects

Each drug influences estrogen signaling, but through different pathways that produce distinct adverse-effect patterns.

AndroGel raises testosterone, a portion of which converts to estradiol through aromatization. In some men, particularly those with higher body fat percentages, this can produce elevated estradiol levels leading to gynecomastia, breast tenderness, and fluid retention [3]. Prescribers sometimes add an aromatase inhibitor (anastrozole) to manage this, though the Endocrine Society guideline does not recommend routine co-prescribing of aromatase inhibitors with testosterone therapy [3].

Enclomiphene blocks hypothalamic estrogen receptors. This is how it works. But that same receptor blockade can produce SERM class effects: hot flashes, visual disturbances (including blurred vision and photophobia), and headache [1]. Visual symptoms are well documented with clomiphene citrate and attributed to retinal effects of estrogen receptor antagonism. The incidence with pure enclomiphene appears lower than with the racemic mixture (which includes zuclomiphene, the cis-isomer with longer half-life and stronger estrogenic activity), but direct comparison data are limited 11.

Hot flashes on enclomiphene tend to be mild and transient. They occur because the hypothalamus, partially blocked from sensing circulating estrogen, mimics the estrogen-deficient state seen in menopause. The clinical significance is low for most men, but it should be disclosed during informed consent.

Hepatic and Metabolic Considerations

Neither drug carries a black-box hepatotoxicity warning, but their metabolic profiles differ.

AndroGel's prescribing information notes that testosterone replacement can worsen pre-existing sleep apnea, alter lipid profiles (typically lowering HDL cholesterol by 5 to 15%), and affect glucose metabolism [9]. The TRAVERSE trial found no significant difference in the incidence of type 2 diabetes between testosterone and placebo groups, but lipid changes were confirmed [8].

Enclomiphene, as a SERM, has theoretical hepatic effects. Clomiphene citrate (the racemic compound) has rare case reports of liver enzyme elevation. An analysis in the Journal of Clinical Endocrinology and Metabolism examining SERMs in male hypogonadism found no consistent hepatotoxicity signal with short-to-medium-term use 12. Long-term safety data beyond 12 months remain sparse for enclomiphene specifically.

For lipid management, one potential advantage of enclomiphene is that SERMs tend to raise HDL and lower LDL, an effect well characterized with tamoxifen and raloxifene. Whether enclomiphene replicates this pattern at the doses used for male hypogonadism has not been studied in a dedicated lipid outcomes trial.

Bone Density and Body Composition

Both drugs affect bone and muscle, though through different timelines and magnitudes.

The TTrials bone substudy found that testosterone gel significantly increased volumetric bone mineral density of the spine by 7.5% and estimated bone strength of the spine by 10.8% over 12 months compared to placebo 13. These results were measured by quantitative CT in men aged 65 and older with low testosterone.

Enclomiphene, by restoring endogenous testosterone and maintaining estradiol signaling, would be expected to support bone density. Direct bone density data from enclomiphene-specific trials have not been published. The theoretical concern is that hypothalamic estrogen receptor blockade could partially attenuate estrogen's bone-protective effects, but this has not been demonstrated clinically.

For body composition, the TTrials showed modest benefits with testosterone gel: increased lean mass by a mean of 1.2 kg and decreased fat mass by 1.0 kg over 12 months [2]. Enclomiphene's body composition effects are less well characterized. Short studies indicate improvement in lean mass, but the magnitude has not been directly compared to exogenous testosterone.

Mood, Energy, and Sexual Function Side Effects

Both drugs improve hypogonadal symptoms, but they can also produce mood-related adverse effects.

The TTrials sexual function substudy found that testosterone gel improved sexual desire and erectile function significantly more than placebo, with effect sizes that diminished after the first 6 months 14. Adverse mood effects with AndroGel can include irritability, mood swings, and in rare cases, aggressive behavior, particularly if testosterone levels are pushed supraphysiologic [9].

Enclomiphene restores testosterone levels more gradually, and published trials report improvements in libido and energy without significant mood adverse events [1]. Some clinicians report, anecdotally, that patients on SERMs describe a subjective difference in "well-being" compared to exogenous testosterone, feeling less strong improvement in mood despite similar testosterone numbers. This observation has not been confirmed in controlled studies, and it may relate to the estrogen receptor modulation affecting central nervous system pathways beyond the HPT axis.

Dr. Mohit Khera, a urologist at Baylor College of Medicine who has published extensively on male hypogonadism management, has noted: "The choice between a SERM and exogenous testosterone often comes down to the patient's priorities. If fertility is on the table, the SERM wins. If the patient has completed family building and wants the strongest symptomatic benefit, testosterone replacement is the standard" 15.

Who Should Choose Which Drug

The side-effect profile comparison points to clear clinical decision pathways based on patient characteristics.

Men under 40 who want children now or in the future should default to enclomiphene (or another SERM). The fertility suppression risk with AndroGel is too high to accept when a viable alternative exists. Men with obstructive sleep apnea or baseline hematocrit above 50% face elevated polycythemia risk on exogenous testosterone and may be better candidates for enclomiphene. Men with young children or pregnant partners at home should consider the secondary transfer risk of testosterone gel.

AndroGel remains appropriate for men who have completed family planning, who prefer the well-characterized symptom relief of direct testosterone replacement, and who can adhere to application-site hygiene protocols. Men who develop intolerable hot flashes or visual disturbances on enclomiphene may need to switch to exogenous testosterone.

Both groups require monitoring. Men on AndroGel need hematocrit checks at 3 months, 6 months, and annually. Men on enclomiphene need periodic testosterone and estradiol levels, along with assessment for visual symptoms. Neither drug should be prescribed without confirming the diagnosis of hypogonadism through two morning total testosterone measurements below 300 ng/dL, per Endocrine Society criteria [3].